Cytosorbents Corporation provided product sales guidance for the second quarter of 2021. The company has not historically given specific financial guidance on quarterly results until the quarter has been completed. However, should current underlying order patterns continue, with strength in core business and global demand for CytoSorb to treat COVID-19 patients, as well as ability to continue to scale up and produce CytoSorb, the company expects second quarter 2021 product sales will exceed product sales reported in the second quarter of 2020.